A number of research firms have changed their ratings and price targets for Mentari Therapeutics (NASDAQ: MTRI):
- 11/13/2026 – Mentari Therapeutics is now covered by Wedbush. They set an “outperform” rating and a $33.00 price target on the stock.
- 11/11/2026 – Mentari Therapeutics is now covered by Zacks Research. They set a “hold” rating on the stock.
- 11/11/2026 – Mentari Therapeutics is now covered by TD Cowen. They set a “strong-buy” rating on the stock.
- 11/10/2026 – Mentari Therapeutics is now covered by Jefferies Financial Group. They set a “buy” rating and a $30.00 price target on the stock.
- 11/10/2026 – Mentari Therapeutics is now covered by Stifel Nicolaus. They set a “buy” rating and a $30.00 price target on the stock.
- 11/9/2026 – Mentari Therapeutics is now covered by Guggenheim. They set a “strong-buy” rating on the stock.
Mentari Therapeutics Price Performance
NASDAQ MTRI traded down $1.79 on Tuesday, reaching $18.07. The company had a trading volume of 156,386 shares, compared to its average volume of 79,503. Mentari Therapeutics has a 52-week low of $5.75 and a 52-week high of $23.30.
Insider Activity at Mentari Therapeutics
In other news, major shareholder Adar1 Capital Management, Llc purchased 2,640 shares of the business’s stock in a transaction that occurred on Thursday, November 5th. The shares were acquired at an average cost of $13.10 per share, for a total transaction of $34,584.00. Following the completion of the acquisition, the insider owned 98,297 shares in the company, valued at $1,287,690.70. This trade represents a 2.76% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 0.85% of the stock is currently owned by corporate insiders.
Read More
- Five stocks we like better than Mentari Therapeutics
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Receive News & Ratings for Mentari Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mentari Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
